Evidence map›Paper›PMID 33129741›Full record

ArticleJACC. Cardiovascular imaging2021

Machine Learning Adds to Clinical and CAC Assessments in Predicting 10-Year CHD and CVD Deaths.

Rine Nakanishi, Piotr J Slomka, Richard Rios, Julian Betancur, Michael J Blaha, Khurram Nasir, Michael D Miedema, John A Rumberger, Heidi Gransar, Leslee J Shaw and 3 more

Open access · greenAbstract read
In one paragraph

Article in JACC. Cardiovascular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 3 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Development of an artificial intelligence algorithm for automated detection of cardiovascular intervention-related complications.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Rine NakanishiDepartment of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan; Los Angeles BioMedical Research Institute at Harbor UCLA Medical Center, Torrance, California, USA.
Piotr J SlomkaDepartment of Imaging (Division of Nuclear Medicine), Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA; David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Electronic address: piotr.slomka@cshs.org.
Richard RiosDepartment of Imaging (Division of Nuclear Medicine), Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Julian BetancurDepartment of Imaging (Division of Nuclear Medicine), Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Michael J BlahaPrevention of Heart Disease, Division of Cardiology, Department of Medicine, Johns Hopkins Ciccarone Center, Baltimore, Maryland, USA.
Khurram NasirCenter for Prevention and Wellness Research, Baptist Health Medical Group, Miami Beach, Florida, USA.
Michael D MiedemaMinneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
John A RumbergerDepartment of Cardiac Imaging, The Princeton Longevity Center, Princeton, New Jersey, USA.
Heidi GransarDepartment of Imaging (Division of Nuclear Medicine), Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Leslee J ShawWeill Cornell Medical College, New York, New York, USA.
Alan RozanskiDivision of Cardiology, Mount Sinai St. Luke's Hospital, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Matthew J BudoffLos Angeles BioMedical Research Institute at Harbor UCLA Medical Center, Torrance, California, USA.
Daniel S BermanDepartment of Imaging (Division of Nuclear Medicine), Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA; David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Baptist Hospital of Miami · USCedars-Sinai Medical Center · USCornell University · USHarbor–UCLA Medical Center · USMinneapolis Heart Institute Foundation · USPrinceton University · US

Funding

Quantitative Prediction of Disease and Outcomes from Next Generation SPECT and CTR01HL089765 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI SLOMKA, PIOTR J · 2007 to 2021
$6.1M
NHLBI NIH HHS L30 HL110027NHLBI NIH HHS R01 HL089765
6 · The paper itself

Abstract

objectivesThe aim of this study was to evaluate whether machine learning (ML) of noncontrast computed tomographic (CT) and clinical variables improves the prediction of atherosclerotic cardiovascular disease (ASCVD) and coronary heart disease (CHD) deaths compared with coronary artery calcium (CAC) Agatston scoring and clinical data.

backgroundThe CAC score provides a measure of the global burden of coronary atherosclerosis, and its long-term prognostic utility has been consistently shown to have incremental value over clinical risk assessment. However, current approaches fail to integrate all available CT and clinical variables for comprehensive risk assessment.

methodsThe study included data from 66,636 asymptomatic subjects (mean age 54 ± 11 years, 67% men) without established ASCVD undergoing CAC scanning and followed for cardiovascular disease (CVD) and CHD deaths at 10 years. Clinical risk assessment incorporated the ASCVD risk score. For ML, an ensemble boosting approach was used to fit a predictive classifier for outcomes, followed by automated feature selection using information gain ratio. The model-building process incorporated all available clinical and CT data, including the CAC score; the number, volume, and density of CAC plaques; and extracoronary scores; comprising a total of 77 variables. The overall proposed model (ML all) was evaluated using a 10-fold cross-validation framework on the population data and area under the curve (AUC) as metrics. The prediction performance was also compared with 2 traditional scores (ASCVD risk and CAC score) and 2 additional models that were trained using all the clinical data (ML clinical) and CT variables (ML CT).

resultsThe AUC by ML all (0.845) for predicting CVD death was superior compared with those obtained by ASCVD risk alone (0.821), CAC score alone (0.781), and ML CT alone (0.804) (p < 0.001 for all). Similarly, for predicting CHD death, AUC by ML all (0.860) was superior to the other analyses (0.835 for ASCVD risk, 0.816 for CAC, and 0.827 for ML CT; p < 0.001).

conclusionsThe comprehensive ML model was superior to ASCVD risk, CAC score, and an ML model fitted using CT variables alone in the prediction of both CVD and CHD death.

Indexed as

AtherosclerosisCardiovascular DiseasesCoronary Artery DiseaseAdultAgedFemaleHumansMachine LearningMaleMiddle AgedPredictive Value of Testscardiovascular disease deathcoronary artery calcificationcoronary heart disease deathmachine learningpooled cohort equation

Identifiers

PMID33129741
PMCPMC7987201
OpenAlexW3097577799

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.